COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,878 Articles (22,568 medRxiv, 8,310 bioRxiv)

Most recent first Previous |  Page 2868: Articles 28671-28680  | Next

Collateral damage: the impact on cancer outcomes of the COVID-19pandemic
Sud, A., Jones, M. E., Broggio, J., Loveday, C., Torr, B., Garrett, A., Nicol, D. L., Jhanji, S., Boyce, S. A., Ward, P., Handy, J. M., Yousaf, N., Larkin, J., Suh, Y.-E., Scott, S., Pharoah, P. D. P., Swanton, C., Abbosh, C., Williams, M., Lyratzopoulos, G., Houlston, R., Turnbull, C.
10.1101/2020.04.21.20073833 — Posted: 2020-04-24
Covid-19 and Inequity: A comparative spatial analysis of New York City and Chicago hot spots
Maroko, A. R., Nash, D., Pavilonis, B.
10.1101/2020.04.21.20074468 — Posted: 2020-04-24
Risk of drug-induced Long QT Syndrome associated with the use of repurposed COVID-19 drugs: a systematic review
Turgeon, J., Michaud, V., Dow, P., Al Rihani, S. R., Deodhar, M., Arwood, M., Cicali, B.
10.1101/2020.04.21.20066761 — Posted: 2020-04-24
ACE2 Homo-dimerization, Human Genomic variants and Interaction of Host Proteins Explain High Population Specific Differences in Outcomes of COVID19
Sharma, S., Singh, I., Haider, S., Malik, M. Z., Ponnusamy, K., Rai, E.
10.1101/2020.04.24.050534 — Posted: 2020-04-24 Discussion: Onsite
ACE2 polymorphisms and individual susceptibility to SARS-CoV-2 infection: insights from an in silico study
Calcagnile, M., Forgez, P., Iannelli, A., Bucci, C., Alifano, M., Alifano, P.
10.1101/2020.04.23.057042 — Posted: 2020-04-24
Validation of a SARS-CoV-2 spike ELISA for use in contact investigations and serosurveillance
Freeman, B., Lester, S., Mills, L., Rasheed, M. A. U., Moye, S., Abiona, O., Hutchinson, G., Morales-Betoulle, M., Krapinunaya, I., Gibbons, A., Chiang, C.-F., Cannon, D., Klena, J., Johnson, J. A., Owen, S. M., Graham, B. S., Corbett, K. S., Thornburg, N. J.
10.1101/2020.04.24.057323 — Posted: 2020-04-24
Evolution and molecular characteristics of SARS-CoV-2 genome
Bai, Y., Jiang, D., Lon, J. R., Chen, X., Hu, M., Lin, S., Chen, Z., Meng, Y., Du, H.
10.1101/2020.04.24.058933 — Posted: 2020-04-24 Discussion: Onsite
Genomic, geographic and temporal distributions of SARS-CoV-2 mutations
Yang, H.-C., Chen, C.-h., Wang, J.-H., Liao, H.-C., Yang, C.-T., Chen, C.-W., Lin, Y.-C., Kao, C.-H., Liao, J. C.
10.1101/2020.04.22.055863 — Posted: 2020-04-24
Critical role of type III interferon in controlling SARS-CoV-2 infection, replication and spread in primary human intestinal epithelial cells
Stanifer, M. L., Kee, C., Cortese, M., triana, S., Mukenhirn, M., Kraeusslich, H.-G., Alexandrov, T., Bartenschlager, R., Boulant, S.
10.1101/2020.04.24.059667 — Posted: 2020-04-24 Discussion: Offsite
Introductions and early spread of SARS-CoV-2 in France
Gambaro, F., Baidaliuk, A., Behillil, S., Donati, F., Albert, M., Alexandru, A., Vanpeene, M., Bizard, M., Brisebarre, A., Barbet, M., Derrar, F., van der Werf, S., Enouf, V., Simon-Loriere, E.
10.1101/2020.04.24.059576 — Posted: 2020-04-24 Discussion: Offsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).